A data analysis from a randomized clinical trial for stage 3 colon cancer patients found that patients with evidence of residual cancer in their blood after surgery to remove the cancer, may benefit from adding of celecoxib, to post surgery treatment.
Blood test could guide use of anti-inflammatory drug celecoxib to reduce risk of colon cancer recurrence
